Preclinical lead development of ADAM10 enhancing molecules for the treatment of Alzheimer's dementia

• Unité de recherche: INNOSUISSE
• Numéro de projet: 119.341 IP-LS
• Titre du projet anglais: Preclinical lead development of ADAM10 enhancing molecules for the treatment of Alzheimer's dementia

Mots-clé (Anglais)

Life sciences, Pharmaceuticals

Résumé des résultats (Abstract) (Anglais)

Abnormal processing of amyloid precursor protein (APP) and accumulation of amyloid-beta peptides is a hallmark of Alzheimer's dementia. The protease ADAM10 neuroprotectively cleaves APP, blocking the accumulation of amyloid-beta peptides. We aim to develope molecules to enhance ADAM10 activity.